Second-Line LR- MDS Setting: Treatment Options and Considerations

Author(s):

James K. McCloskey, MD, John Theurer Cancer Center,Thomas W. LeBlanc, MD, MA

Panelists discuss how they determine thresholds for changing therapy in patients with MDS, evaluate second-line treatment options including the potential use of ESAs after luspatercept, and offer key takeaways for community colleagues managing similar clinical scenarios.

EP: 1.Understanding Myelodysplastic Syndromes (MDS): Diagnosis, Classification, and Risk Assessment

EP: 2.Navigating the Heterogeneity of LR-MDS: Importance of Molecular Testing & Risk Stratifying

EP: 3.Clinical Scenario 1: 76-Year-Old Man With Newly Diagnosed MDS With Symptomatic Anemia, RS Positive

EP: 4.Tailoring Treatment for LR-MDS: Patient Factors, Treatment Goals, and Patient Outcomes

EP: 5.First-Line Luspatercept in LR-MDS: A Deep Dive Into the COMMANDS Trial and Clinical Implications in the Real-Life Practice Setting

EP: 6.Managing Luspatercept Therapy: Dosing, Adverse Effects, and Monitoring

Now Viewing

EP: 7.Second-Line LR- MDS Setting: Treatment Options and Considerations

EP: 8.Patient Profile: 66-Year-Old Woman with Newly Diagnosed LR-MDS, RS Negative

EP: 9.Luspatercept Role in the RS-Negative Population and Expert Perspectives on the Role of EPO Levels

EP: 10.First-Line ESA vs Luspatercept in LR-MDS: Choosing the Most Appropriate Treatment Option for Each Individual Patient

EP: 11.Imetelstat and IMerge Trial Review

EP: 12.Looking Ahead in LR-MDS: Future Agents and/or Combination Strategies

EP: 13.The Future of Lower-Risk MDS: Closing Thoughts and Unmet Needs

Video content above is prompted by the following:

What is your threshold for changing therapy in your clinical practice?
What treatment options would you consider in the second-line setting for this patient? Do you consider trialing ESAs post luspatercept?
What are some key takeaways you can offer community colleagues from this clinical scenario and discussion?